{{distinguish|5F-APINACA}}
{{Drugbox
| IUPAC_name = N-[(2''S'')-1-amino-3-methyl-1-oxobutan-2-yl]-1-(5-fluoropentyl)indazole-3-carboxamide
| image = 5F-AB-PINACA.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_DE = Anlage II
| legal_status = Illegal in China and Singapore
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 1800101-60-3
| ATC_prefix =  
| ATC_suffix =  
| UNII = 3L83B2298V
| PubChem = 91936927
| ChemSpiderID      = 29763723

<!--Chemical data-->
| C=18 | H=25 | F=1 | N=4 | O=2
| molecular_weight =
|  StdInChI = 1S/C18H25FN4O2/c1-12(2)15(17(20)24)21-18(25)16-13-8-4-5-9-14(13)23(22-16)11-7-3-6-10-19/h4-5,8-9,12,15H,3,6-7,10-11H2,1-2H3,(H2,20,24)(H,21,25)/t15-/m0/s1
|  StdInChIKey = WCBYXIBEPFZUBG-HNNXBMFYSA-N
|  smiles = CC(C)[C@H](NC(=O)c1nn(CCCCCF)c2ccccc12)C(N)=O
}}

'''5F-AB-PINACA''' is an [[indazole]]-based [[synthetic cannabinoid]] that is derived from a series of compounds originally developed by [[Pfizer]] in 2009 as an [[analgesic]] medication, and has been sold online as a [[designer drug]].<ref>{{cite journal | url=https://www.google.com/patents/WO2009106980A3 | title=Patent WO/2009/106980 - Indazole derivatives}}</ref><ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/14755 | title=5F-AB-PINACA| publisher=Cayman Chemical | accessdate=5 July 2015}}</ref>

5F-AB-PINACA has been reported to be a potent [[agonist]] of the [[CB1 receptor|CB<sub>1</sub> receptor]] and [[CB2 receptor|CB<sub>2</sub> receptor]] with [[EC50|EC<sub>50</sub>]] values of 0.48&nbsp;nM and 2.6&nbsp;nM respectively.<ref>{{cite journal | author10=Michelle Glass | author11=Mark Connor | author12=Iain S. McGregor | author13=Michael Kassiou | url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00112 | title=Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA | date=September 2015 | author=Samuel D. Banister | author2=Michael Moir | author3=Jordyn Stuart | author4=Richard C. Kevin | author5=Katie E. Wood | author6=Mitchell Longworth | author7=Shane M. Wilkinson | author8=Corinne Beinat | author9=Alxendra S. Buchanan | journal=ACS Chemical Neuroscience | volume=6 | issue=9 | pages=1546–1559 | doi=10.1021/acschemneuro.5b00112 | pmid=26134475}}</ref> Its metabolism has been described in literature.<ref>{{cite journal | title=Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA | date=May 2015 | author=Ariane Wohlfarth | author2=Marisol S. Castaneto | author3=Mingshe Zhu | author4=Shaokun Pang | author5=Karl B. Scheidweiler | author6=Robert Kronstrand | author7=Marilyn A. Huestis | journal=The AAPS Journal | volume=17 | issue=3 | pages=660–677 | doi=10.1208/s12248-015-9721-0 | pmid=25721194 | PMC=4406957}}</ref><ref>{{cite journal | url=https://link.springer.com/article/10.1007/s11419-015-0265-x | title=Simultaneous quantification of 37 synthetic cannabinoid metabolites in human urine by liquid chromatography-tandem mass spectrometry | date=July 2015 | author=Moonhee Jang | author2=Ilchung Shin | author3=Jihyun Kim | author4=Wonkyung Yang | journal=Forensic Toxicology | volume=33 | issue=2 | pages=221–234 | doi=10.1007/s11419-015-0265-x}}</ref>

==Legality==

===China===
As of October 2015 5F-AB-PINACA is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

===Germany===
5F-AB-PINACA is an [[Drugs controlled by the German Betäubungsmittelgesetz|Anlage II]] controlled substance in Germany as of May 2015.<ref>{{cite web | url=http://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html | title=Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel) | accessdate=5 July 2015 | language=German}}</ref>

===Singapore===
It is also controlled under the Fifth Schedule of the Misuse of Drugs Act (MDA) in Singapore as of May 2015.<ref>{{cite web | url=http://www.cnb.gov.sg/Libraries/CNB_Newsroom_Files/CNB_NR_-_30_Apr_2015.sflb.ashx | title=CNB NEWS RELEASE | publisher=Central Narcotics Bureau (CNB) | date=30 April 2015 | accessdate=24 July 2015}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-ADB]]
* [[5F-AMB]]
* [[5F-CUMYL-PINACA]]
* [[AB-FUBINACA]]
* [[AB-CHFUPYCA]]
* [[AB-PINACA]]
* [[ADB-CHMINACA]]
* [[ADB-FUBINACA]]
* [[ADB-PINACA]]
* [[ADBICA]]
* [[APICA]]
* [[APINACA]]
* [[MDMB-CHMICA]]
* [[PX-3]]
{{Div col end}}

==References==
<references/>

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indazolecarboxamides]]
[[Category:Fluoroalkanes]]
[[Category:CB1 receptor agonists]]
[[Category:CB2 receptor agonists]]


{{cannabinoid-stub}}